Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.
about
International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney diseaseDifference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO studyRecent progress in the treatment of cardiovascular disease using olmesartan.How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?
P2860
Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@en
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@nl
type
label
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@en
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@nl
prefLabel
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@en
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@nl
P2093
P2860
P1476
Clinical and pharmacotherapeut ...... 1 receptor blocker olmesartan.
@en
P2093
Keijiro Saku
Masahiro Fujino
Sadashiva S Karnik
Satoshi Imaizumi
Shin-Ichiro Miura
Yoshihiro Kiya
P2860
P304
P356
10.3109/10641960903254430
P577
2010-01-01T00:00:00Z